{'52WeekChange': -0.36498147,
 'SandP52WeekChange': None,
 'address1': '3 Lochside Way',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.95,
 'askSize': 1000,
 'averageDailyVolume10Day': 116650,
 'averageVolume': 73947,
 'averageVolume10days': 116650,
 'beta': 1.091232,
 'beta3Year': None,
 'bid': 5.75,
 'bidSize': 800,
 'bookValue': 3.5,
 'category': None,
 'circulatingSupply': None,
 'city': 'Edinburgh',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.8,
 'dayLow': 5.43,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 179402192,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.577343,
 'fiftyTwoWeekHigh': 10.94,
 'fiftyTwoWeekLow': 3.81,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16312808,
 'forwardEps': -73.29,
 'forwardPE': -0.07654523,
 'fromCurrency': None,
 'fullTimeEmployees': 29,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0065499996,
 'heldPercentInstitutions': 0.49377,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/nucana.com',
 'longBusinessSummary': 'NuCana plc, a clinical-stage biopharmaceutical '
                        'company, engages in the development of products for '
                        'the treatment of cancer. The company develops its '
                        'products based on its proprietary ProTide technology. '
                        'Its lead product candidate includes Acelarin, which '
                        'is in Phase Ib and Phase III clinical trials for the '
                        'treatment of patients with biliary tract cancer; a '
                        'Phase II clinical trial for the treatment of patients '
                        'with platinum-resistant ovarian cancer; Phase Ib '
                        'clinical trial for the treatment of patients with '
                        'biliary cancer; and Phase III clinical trial for the '
                        'treatment of patients with metastatic pancreatic '
                        'cancer. The company is also developing NUC-3373, a '
                        'ProTide transformation of the active anti-cancer '
                        'metabolite of 5-fluorouracil, which is in Phase I '
                        'clinical trial for the treatment of patients with '
                        'advanced solid tumors; and NUC-7738, a nucleoside '
                        'analog that is in Phase I clinical trial for the '
                        'treatment of patients with advanced solid tumors and '
                        'hematological tumors. NuCana plc has a research, '
                        'collaboration, and license agreement with Cardiff '
                        'University and University College Cardiff Consultants '
                        'Ltd. for the design, synthesis, characterization, and '
                        'evaluation of ProTides; and an assignment, license, '
                        'and collaboration agreement with Cardiff ProTides '
                        'Ltd. The company was formerly known as NuCana BioMed '
                        'Limited and changed its name to NuCana plc in August '
                        '2017. NuCana plc was incorporated in 1997 and is '
                        'headquartered in Edinburgh, the United Kingdom.',
 'longName': 'NuCana plc',
 'market': 'us_market',
 'marketCap': 182207200,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_50918463',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.51,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 13 1357 1111',
 'previousClose': 5.15,
 'priceHint': 2,
 'priceToBook': 1.6028572,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.8,
 'regularMarketDayLow': 5.43,
 'regularMarketOpen': 5.51,
 'regularMarketPreviousClose': 5.15,
 'regularMarketPrice': 5.51,
 'regularMarketVolume': 684163,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 32479000,
 'sharesPercentSharesOut': 0.0764,
 'sharesShort': 2482707,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2469732,
 'shortName': 'NuCana plc',
 'shortPercentOfFloat': None,
 'shortRatio': 39.47,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'NCNA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.634,
 'twoHundredDayAverage': 5.592547,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'dfdec38b-ab4c-3c50-b808-03a61a463a78',
 'volume': 684163,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.nucana.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'EH12 9DT'}